Completed

REVEAL-VascA Cross-sectional REVEAL Sub-study Evaluating the Effect of Anacetrapib on Vascular Function and Arterial Stiffness [An Investigator Led Sub-study of HPS3/TIMI 55: REVEAL]

What is being collected

Data Collection

Collected at a single point in time - Cross-sectional

No DNA Sample

Who is being recruted

Arterial Occlusive Diseases+4

+ Arteriosclerosis

+ Behavior

Over 50 Years

+6 Eligibility Criteria

See all eligibility criteria

How is the trial designed

Cohort

Tracking disease incidence in order to identify risk factors and understand disease progression over time.

Observational

Study Start: January 2017

See protocol details

Summary

Principal SponsorCambridge University Hospitals NHS Foundation Trust

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Study start date: January 1, 2017

Actual date on which the first participant was enrolled.

REVEAL-Vasc is an investigator led sub-study of HPS3/TIMI 55: REVEAL. Participants who previously enrolled on HPS3/TIMI 55: REVEAL and received treatment will be invited to participate in this sub-study. Participants will attend a screening and an assessment visit during which Pulse Wave Velocity/ Pulse Wave Analysis and Flow Mediated Dilation will be carried out to assess blood vessel function and stiffness. A blood sample will also be taken from participant to assess CRP and lipid profile. Since participants will have received treatment on the main trial HPS3/TIMI 55: REVEAL, no treatment will be received on this sub-study.

Official TitleA Cross-sectional REVEAL Sub-study Evaluating the Effect of Anacetrapib on Vascular Function and Arterial Stiffness [An Investigator Led Sub-study of HPS3/TIMI 55: REVEAL]

NCT02931188

Principal SponsorCambridge University Hospitals NHS Foundation Trust

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

103 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Cohort

These studies follow a group of individuals with common characteristics (such as a condition or birth year) over a specific period to study health outcomes or exposures.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.

Conditions

Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 50 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Arterial Occlusive DiseasesArteriosclerosisBehaviorCardiovascular DiseasesInhibition, PsychologicalVascular DiseasesAtherosclerosis

Criteria

1 inclusion criteria required to participate

Participants who have been randomised into the HPS3/TIMI 55- REVEAL study (NCT01252953)

5 exclusion criteria prevent from participating

Any concomitant condition that, at the discretion of the investigator, may affect the participant's ability to complete the study or study procedures

Atrial fibrillation at time of assessment

Inability to provide informed consent

Inability to refrain from caffeine containing products for 6 hours prior to study visit

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Clinical Investigation Ward, Addenbrooke's Hospital

Cambridge, United KingdomOpen Clinical Investigation Ward, Addenbrooke's Hospital in Google Maps

CompletedOne Study Center